Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alphamab Oncology ( (HK:9966) ) has provided an update.
Alphamab Oncology announced that its drug JSKN003 has received Fast Track Designation from the U.S. FDA for treating platinum-resistant recurrent epithelial ovarian cancer and related conditions. This designation highlights the promising clinical data and potential of JSKN003, which has also received multiple designations for other cancers, indicating strong international regulatory confidence. The development of JSKN003 addresses a significant unmet need in ovarian cancer treatment, offering improved efficacy over existing therapies and potentially expediting its clinical development and regulatory review.
The most recent analyst rating on (HK:9966) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on Alphamab Oncology stock, see the HK:9966 Stock Forecast page.
More about Alphamab Oncology
Alphamab Oncology is a leading biopharmaceutical company in China, specializing in the development of antibody-drug conjugates (ADCs), bispecific antibodies, and multifunctional protein engineering for oncology treatment. The company boasts a fully integrated proprietary technology platform and an in-house pipeline of differentiated products, including ADCs and monoclonal antibodies in various stages of clinical development.
Average Trading Volume: 4,238,962
Technical Sentiment Signal: Buy
Current Market Cap: HK$11.53B
For detailed information about 9966 stock, go to TipRanks’ Stock Analysis page.